


Emerging Health Concerns in the Era of Cannabis Legalization

Iyad N. Daher, MD, FACC, FASE, FSCCT
Chief Science Officer, VRX Labs

Cannabis legalization is advancing worldwide





Legalization impact on population use and health hazards

- More first-time users
- More volume of consumption (more exposure)
- More matrices (smoke/vape/cookies/gummies/drinks)
- More access to vulnerable populations (young, elderly, cancer, immunocompromised, fertile females, pregnant)
- More potential for inappropriate/accidental use (young, driving, operating machinery)
- More apparent cannabis related medical problems (increased reporting)



Cannabis population health impact is yet to be fully understood

- Limited US federal funding
- Restrictions on research even with private funds (stigma, loss of federal funding)
- Paucity of quality data (small numbers, case reports, no longitudinal studies, biases (reporting/publishing/authors/editors/reviewers))
- Post marketing studies NOT mandated at this time



How do these concerns compare with alcohol?

Alcohol like

- first time users
- Increased exposure
- vulnerable populations (young, pregnant)
- inappropriate/accidental use (young, driving, operating machinery)
- More apparent

Cannabis specific


- Increased cannabis related medical problems (psychiatric, bad experience, contaminants)
- More matrices (smoke/vape/cookies/gummies/drinks)
- vulnerable populations (elderly, cancer, immunocompromised, fertile or pregnant females): contaminants



Comparison to alcohol is useful but has limitations

- ▶ Cannabis and derived THC/CBD have medical applications.
- ▶ Addiction potential is not completely overlapping.
- ▶ Medical and psychiatric complications are different.
- ▶ Cannabis products medical risks are mostly (exceptions include CBD and liver toxicity) due to contaminants.

Cannabis processing overview





How do we optimize the safety and quality of cannabis products?

Contaminants

- ▶ Foreign Material
- ▶ Water Activity
- ▶ Residual Solvents
- ▶ Residual Pesticides
- ▶ Heavy Metals
- ▶ Mycotoxins
- ▶ Microbials

Profiling

- ▶ Cannabinoids
- ▶ Terpenes



Pesticides, herbicides and fungicides

How do plants get
contaminated?

- Direct application
- Drifting from other fields
(outdoor grows)
- Systemic (pesticides that are
absorbed by the plant can be
passed on in clones)

Pesticides of concern:

- Eagle 20 (Myclobutanil)
- Imidacloprid
- Abamectin
- Etoxazole
- Spiromesifen
- >60 different pesticides are tested
for in California!



Prevalence of cannabis pesticide contamination

- ▶ Pesticide use for the cultivation of cannabis crops (pre and post legalization) is well established.
- ▶ An early study of medicinal cannabis in California found excessive quantities of the pesticide Bifenthrin.
- ▶ Up to 85% of legalized cannabis products in Washington State were found in one study to contain significant quantities of insecticides, fungicides, miticides and herbicides.
- ▶ in vitro study showed that up to 60% of pesticide residues in smoke stream are transferred to end user as measured by gas chromatography.



Potential toxicities of pesticides in cannabis

- A vast array of possible toxicities including malignancy, developmental issues, reproductive, neurological and endocrine disorders.
- Identified carcinogens present in cannabis include vinyl chloride, nitrosamines, reactive oxygen species and polycyclic aromatic hydrocarbons, notably benzopyrene and benzanthracene.
- When heated (smoked) myclobutanil degradation yields arsenic.
- Various pesticides, particularly organophosphate insecticides are recognized endocrine disruptors, and may interfere with normal fertility function and developmental processes.



Legislative/regulatory issues

- ▶ Which pesticides are safe to use (if any) and which ones to test for (up to 66 in CA)
- ▶ What is the Maximal Residue Limit (MRL) of each pesticides used
- ▶ Where to test for pesticides (independent labs vs state labs)
- ▶ How to make sure that labs use accurate methods (LOD/LOQ, full spectrum testing, inter/intra obs. variability)



Residual solvents in cannabis

Commonly used solvents
to extract oils
from cannabis flower:

- Acetone
- Propane
- Butane
- Ethanol

- CO2 extraction is “solvent-free” but more costly

Possible health
concerns:


- Impurities/contaminants in solvents themselves
- Incomplete purging of solvents by rotary evaporation or a vacuum oven

Heavy metals in cannabis

Cannabis/Hemp
are metal hyperaccumulators

- Historically, hemp has been used to prepare soil for planting food crops.
- Cannabis plant can grow despite high metal soil content.
- Absorbs and concentrates metals.
- Cannabis and hemp plant may be used as “phytoremediator” of heavy metals and other pollutants.

Phytoremediation



Can you spot the difference?



Grown with Advanced Nutrients



Grown with Cadmium, Mercury, Lead, Arsenic, Nickel

Cannabis can contain heavy metals such as cadmium, mercury, lead, arsenic and nickel.

Discover the dangers of heavy metal toxicity at:
[AdvancedNutrients.com/HeavyMetal](https://www.advancednutrients.com/heavymetal)

And remember to always ask,
“Was it grown with Advanced Nutrients?”
for safety before you smoke.

 **Advanced Nutrients**
Raising the Bud Weights... and Reputations... of Top Growers

VRXLABS

Specific heavy metals and their sources

Heavy metals found in cannabis

- Cadmium
- Arsenic
- Lead
- Mercury

- Misc. others: nickel, barium, silver

Metal sources

- Soil
- Water
- Nutrients
- Fertilizers (myclobutanil: arsenic, organophos: cadmium)

- Processing (drying)
- Packaging (vape)
- Intentional (street cannabis)



Heavy metals toxicity from cannabis use:

- Broadly, heavy metals cross GI lumen via para/transcellular routes into the circulation where they may accumulate in various organs.
- Most heavy metals are recognized endocrine disruptors, interfering with fertility and developmental processes.
- Mercury and lead at toxic levels affect neurological development and function.
- Cadmium and arsenic are highly volatile and become carcinogenic under pyrolytic conditions.
- Arsenic is classified by the IARC as Group 1 substance (carcinogenic to humans) due to its causal association with skin, liver and GU cancers.
- Arsenic contamination associated with “cannabis arteritis”, a form of thrombitis obliterans.

Cannabis arteritis: Similar to Buerger's

- Arsenic may be a factor in vascular thrombosis and inflammatory arteritis.
- Possibly inhibits vascular endothelial growth factor and induce endothelial cell apoptosis.
- Case report of 26 year old female heavy cannabis user



El Omri, Naoual et al. "Cannabis arteritis." *The Pan African medical journal* vol. 26 53. 1 Feb. 2017, doi:10.11604/pamj.2017.26.53.11694

Microbial contaminants in cannabis

Common organisms

- Salmonella
- E. Coli
- Aspergillus niger
- Aspergillus terreus
- Aspergillus fumigatus
- Aspergillus flavus
- Others: Klebsiella, Enterobacter, Acinetobacter, Stenotrophomonas, Pseudomonas, Bacillus, Cryptococcus

Contamination source

- Growing
 - Water
 - Nutrients
 - Soil & compost
 - Air
- Processing/storage/sales
 - Hands
 - Coughing, sneezing




Reported and potential impact of cannabis contamination with bacteria

- Enteritis outbreak traced to Salmonella Muenchen in cannabis
- E.coli/Salmonella/Shigella: GI, bloody diarrhea, HUS, Reiter's
- Other enterobacter: GI
- Pseudomonas: PNA
- Aspergillus: PNA, systemic infections, immunocompromized

Case report:

Pseudomonas aeruginosa



- 23 y/o male, daily cannabis smoker for 4 years (preferred method of inhalation: bong/water pipe)
- 3 days of fever, haemoptysis, and dyspnea
- Labs showed high WBC and CRP
- CT scan showed LUL necrotizing PNA with hydropneumothorax
- *P. aeruginosa* recovered from:
 - Sputum
 - pleural fluid
 - bong

Fungal contaminants

- Wet/humid conditions during harvesting can lead to fungal growth and infections after consumption.
- Several toxigenic species of *Aspergillus*, *Penicillium* as well as *Cryptococcus liquefaciens* have been found in commercial cannabis samples.
- Multiple reports of fungal spore contaminants in cannabis products, including mycotoxin-producing strains of *Aspergillus*.
- Vaporized fungal spores are likely to survive smoking temperatures and may cause fungal pneumonia at even very low numbers.
- Several case reports of opportunistic infection with fungi, commonly *Aspergilli*, in immunocompromised patients linked to findings of cannabis contaminated by fungal spores.



Aspergillus spp. Infections traced to cannabis use

➤ CASE 1

- 47 y/o male, tobacco smoker 40 pack-year, 5 joints per day.
- RA patient
- 4 year history of dyspnea, weight loss, coughing thick sputum
- High CRP
- CT scan showed COPD with multiple bullae.
- Bullae extracted via surgery showed an Aspergilloma (fungal ball)

➤ CASE 2

- 43 y/o male, smoked 20 joints per day.
- Predisposing heart condition
- CT showed emphysema and aspergilloma



Mediterr J Hematol Infectious Disease; 2011. Epub 2011 Jan 14
"Too Many Moldy Joints – Marijuana and Chronic Pulmonary Aspergillosis"

Aspergilloma in cannabis user




Prevention and remediation for microbial contaminants in cannabis


- Pharmaceutical grade standards and procedures need to be developed and adopted (inter)nationally.
- This may be achieved at multiple points in the production process:
 - ensuring clean growing media
 - hygienic handling and storing
 - gamma-irradiation of final products
- Accurate production and supply chain tracking
- Public health monitoring for suspected outbreaks
- Adequate education of immunocompromised patients about contaminant risks

Mycotoxins/Aflatoxins in cannabis products

- Mycotoxins are secondary toxic metabolites resulting from fungal contamination and growth.
- Production of mycotoxins can be mitigated by ensuring products are properly dried and stored.
- Mycotoxins of concern in cannabis:
 - Aflatoxin B1, B2, G1, G2 (*A. flavus*, *A. parasiticus*)
 - Ochratoxin A (*A. ochraceus*)



Aflatoxin B1



Aflatoxin B2



Health risks due to aflatoxins in cannabis

- Aflatoxins are classified by the International Agency for Research on Cancer (IARC) as Group 1 substances (carcinogenic to humans) due to their causal association with hepatocellular carcinoma.
- Aflatoxins have been detected in cannabis preparations and smoke.
- Two species of *Aspergillus* (*flavus* and *parasiticus*) showed aflatoxin B1 and G1 production when grown on cannabis versus natural flora substrate.
- Aflatoxins may not be denatured by pasteurization or smoking processes.



Closing comments

- Cannabis legalization driven by public opinion and political will is advancing worldwide.
- Full spectrum of health risks not well defined or included in the legalization process.
- Post marketing/legalization studies needed with the backing of public funds and resources.
- Reevaluation in 5-10 years would yield a more accurate picture.
- Yeast-derived cannabinoids a solution or a different problem?

References

- LM Dryburgh et al. *Br J Clin Pharmacol* (2018)
- United Nations. *Single Convention on Narcotic Drugs, 1961*. New York: United Nations, 1961.
- Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. *Front Pharmacol* 2016;7(309): <https://doi.org/10.3389/fphar.2016.00309>.
- American Herbal Pharmacopeia. *Cannabis Inflorescence: Cannabis spp.; Standards of Identity, Analysis and Quality Control*. ScottsValley, CA: AmericanHerbalPharmacopeia,2013.
- Bolan S, Kunhikrishnan A, Seshadri B, Choppala G, Naidu R, Bolan NS, et al. Sources, distribution, bioavailability, toxicity, and risk assessment of heavy metal(oids) in complementary medicines. *Environ Int* 2017; 108: 103–18.
- McKernan K, Spangler J, Zhang L, Tadigotla V, Helbert Y, Foss T, et al. Cannabis microbiome sequencing reveals several mycotoxic fungi native to dispensary grade Cannabis flowers. *F1000Res* 2015; 4: 1422.
- Taylor D, Wachsmuth K, Shangkuan Y, Schmidt E, Barrett T, Schrader J, et al. Salmonellosis associated with marijuana. *N Engl J Med* 1982; 306: 1249–53.
- Ungerleider JT, Andrysiak T, Tashkin DP, Gale RP. Contamination of marijuana cigarettes with pathogenic bacteria– possible source of infection in cancer patients. *Cancer Treat Rep* 1962; 66: 589.
- Llamas R, Hart DR, Schneider NS. Allergic bronchopulmonary aspergillosis associated with smoking moldy marijuana. *Chest* 1978; 73: 871–2.
- Hamadeh R, Ardehali A, Locksley RM, York MK. Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient. *Chest* 1988; 94: 432–3.
- Remington TL, Fuller J, Chiu I. Chronic necrotizing pulmonary aspergillosis in a patient with diabetes and marijuana use. *CMAJ* 2015; 187: 1305–8.
- Thompson GR, Tuscano JM, Dennis M, Singapuri A, Libertini S, Gaudino R, et al. A microbiome assessment of medical marijuana. *Clin Microbiol Infect* 2017; 23: 269–70.
- Gargani Y, Bishop P, Denning D. Too many mouldy joints – marijuana and chronic pulmonary aspergilliosis. *Mediterr J Hematol Infect Dis* 2011; 3: e2011005.
- Stone D. Cannabis, pesticides and conflicting laws: the dilemma for legalized states and implications for public health. *Regul Toxicol Pharmacol* 2014; 69: 284–8.
- Llewellyn GC, O'Rear CE. Examination of fungal growth and aflatoxin production on marijuana. *Mycopathologia* 1977; 62: 109–12.
- McPartland JM, McKernan KJ. Contaminants of concern in cannabis: microbes, heavy metals and pesticides. In: *Cannabis sativa L – Botany and Biotechnology*, eds Chandra S, Lata H, Elsohly M. Cham, Switzerland: Springer, 2017.
- Busse FP, Fiedler GM, Leichtle A, Hentschel H, Stumvoll M. Lead poisoning due to adulterated marijuana in Leipzig. *Dtsch Arztebl Int* 2008; 105: 757–62.
- Bolan N, Makino T, Kunhikrishnan A. Cadmium contamination and its risk management in rice ecosystems. *Adv Agron* 2013; 119: 183–273.
- Linger P, Müssig J, Fischer H, Kobert J. Industrial hemp (*Cannabis sativa L.*) growing on heavy metal contaminated soil: fibre quality and phytoremediation potential. *Ind Crops Prod* 2002; 16: 33–42.

- Girdhar M, Sharma N, Rehman H, Kumar A, Mohan A. Comparative assessment for hyperaccumulatory and phytoremediation capability of three wild weeds. *3 Biotech* 2014; 4: 579–89.
- Combemale P, Consort T, Denis-Thelis L, Estival J-L, Dupin M, Kanitakis J. Cannabis arteritis. *Br J Dermatol* 2005; 152: 166–9.
- Noel B. Regarding 'Cannabis arteritis revisited – ten new case reports'. *Angiology* 2001; 52: 505–6.
- Sullivan N, Elzinga S, Raber JC. Determination of pesticide residues in cannabis smoke. *J Toxicol* 2013; 2013 (378168): <https://doi.org/10.1155/2013/378168>.
- Skeet N. City Attorney explains medical marijuana issue on NBC. Los Angeles City Attorney website, 10 October 2009 [online]. Available at <http://lacityorgatty.blogspot.com/2009/10/cityattorney-explains-medical.html> (last accessed 8 January 2018).
- McGuinness TM. Update on marijuana. *J Psychosoc Nurs Ment Health Serv* 2009; 47: 19–22.
- Tashkin DP. Smoked marijuana as a cause of lung injury. *Monaldi Arch Chest Dis Pulmonary Series* 2005; 63: 93–100.
- Smith ND. Environmental exposures and genitourinary malignancies. *Urol Oncol Semin Original Invest* 2012;30:196–8.
- Tashkin DP. Effects of marijuana smoking on the lung. *Ann Am Thorac Soc* 2013; 10: 239–47.
- Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking. *J Clin Pharmacol* 2002; 42(S1): 71S–81S.
- Hazekamp A. Evaluating the effects of gamma-irradiation for decontamination of medicinal cannabis. *Front Pharmacol* 2016; 7: 108.
- Moir D, Rickert W, Levasseur G, Larose Y, Maertens R, White P, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. *Chem Res Toxicol* 2008; 21: 494–502.
- International Agency for Research on Cancer. Aflatoxins. IARC monographs on the evaluation of carcinogenic risks to humans [online]. 2018. Available at <https://monographs.iarc.fr/ENG/Monographs/vol100F/mono100F-23.pdf> (last accessed 4 January 2018).
- International Agency for Research on Cancer. Arsenic and arsenic compounds. IARC monographs on the evaluation of carcinogenic risks to humans [online]. 2012. Available at <http://monographs.iarc.fr/ENG/Monographs/vol100C/> (last accessed 5 January 2018).
- Narcotic Drugs Amendment Act 2016 (Cth), Stat. C2016A00012 (2016).
- Stoker TE, Kavlock RJ. Pesticides as endocrine-disrupting chemicals. In: Hayes' Handbook of Pesticide Toxicology, 3rd edn, ed Krieger R. Amsterdam: Elsevier, 2010.
- Dyer CA. Heavy metals and endocrine disrupting chemicals. In: Endocrine-disrupting Chemicals: From Basic Research to Clinical Practice, ed Gore A. Totowa, NJ: Humana Press, 2007.
- Ben-Shabata S, Fridea E, Sheskina T, Tamirib T, Rheec MH, Vogelc Z, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. *Eur J Pharmacol* 1998; 353: 23–31.
- Mechoulam R, Ben-Shabat S. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis. *Nat Prod Rep* 1999; 16: 131–43.
- Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* 2011; 163: 1344–64.
- Abou-Arab AAK, Abou Donia MA. Heavy metals in Egyptian spices and medicinal plants and the effect of processing on their levels. *J Agric Food Chem* 2000; 48: 2300–4.
- Madras K. Update of Cannabis and its Medical Use. Geneva, Switzerland: World Health Organisation Expert Committee on Drug Dependence, 2015.
- Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet* 2003; 42: 327–60.

- Lucas C, Galettis P, Song S, Solowij N, Reuter S, Schneider J, et al. Cannabinoid disposition after human intraperitoneal use: an insight into intraperitoneal pharmacokinetic properties in metastatic cancer. *Clin Ther* 2018; <https://doi.org/10.1016/j.clinthera.2017.12.008>.
- Pizzorno J. What should we tell our patients about marijuana (Cannabis indica and Cannabis sativa)? *Dermatol Int* 2016; 15: 8–12.
- Lorenz W, Bahadir M, Korte F. Thermolysis of pesticide residues during tobacco smoking. *Chemosphere* 1987; 16: 521–2.
- Gartner CE. Mull it over: cannabis vaporizers and harm reduction. *Addiction* 2015; 110: 1709–10.
- Budney AJ, Sargent JD, Lee DC. Vaping cannabis (marijuana): parallel concerns to e-cigs? *Addiction* 2015; 110: 1699–704.
- Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? *Addict Behav* 39: 1430–3.
- Dinis-Oliveira RJ. Metabolomics of Δ^9 -tetrahydrocannabinol: implications in toxicity. *Drug Metab Rev* 2016; 48: 80–7.
- Elchier M, Spinedi L, Uinifer Grauwiler S, Bodmer M, Surber C, Luedi M, et al. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. *Planta Med* 2012; 78: 686–91.
- Buettner C, Mukamal KJ, Gardiner P, Davis RB, Phillips RS, Mittleman MA. Herbal supplement use and blood lead levels of United States adults. *J Gen Intern Med* 2009; 24: 1175–82.
- Grøn C, Andersen L. Human Bioaccessibility of Heavy Metals and PAH from Soil. Hørsholm, Denmark: Danish Environmental Protection Agency, 2003.
- Goldberg A, Meredith PA, Miller S, Moore MR, Thompson GG. Hepatic drug metabolism and haem biosynthesis in lead poisoned rats. *Br J Pharmacol* 1978; 65: 529–36.
- Lowry JA, Pearce RE, Gaedigk A, Venneman M, Talib N, Shaw P, et al. Lead and its effects on cytochromes P450. *J Toxicol* 2006; 5: 1–4.
- Rose RL, Tang J, Choi J, Cao Y, Usmani A, Cherrington N, et al. Pesticide metabolism in humans, including polymorphisms. *Scand J Work Environ Health* 2005; 31: 156–63.
- McPartland JM, Blanchon DJ, Musty RE. Cannabimimetic effects modulated by cholinergic compounds. *Addict Biol* 2008; 13: 411–5.
- Australian Institute of Health and Welfare. Australia's Health 2016 – Illicit Drug Use. Canberra: Australian Institute of Health and Welfare, 2016.
- Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucl Acids Res* 2018; 46 (D1): D1091–106.
- Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. *Br J Pharmacol* 2017; 174: S17–29.
- Degawa M, Aria H, Kubota M, Hashimoto Y. Ionic lead, a unique metal ion as an inhibitor for cytochrome P4501A2 (CYP1A2) expression in the rat liver. *Biochem Biophys Res Commun* 1994; 200: 1086–92.
- Alvares AP, Fischbein A, Sassa S, Anderson KE, Kappas A. Lead intoxication: effects on cytochrome P-450 mediated hepatic oxidases. *Clin Pharmacol Ther* 1976; 19: 183–90.